Unno R, Michishita H, Inagaki H, Suzuki Y, Baba Y, Jomori T, Nishikawa T, Isobe M
Drug Discovery Research Department, Sanwa Kagaku Kenkyusho Co. Ltd, Mie, Japan.
Bioorg Med Chem. 1997 May;5(5):883-901. doi: 10.1016/s0968-0896(97)00026-6.
A series of the 9-acetoxy enediyne compounds, 6a-k which were simplified from natural dynemicin A, and designed to be equipped with various aryl carbamate moieties, was synthesized and evaluated for DNA-cleaving ability, in vitro cytotoxicity, and in vivo antitumor activity. As a result of this study of the structure-activity relationships (SAR) with regard to the Rt substituent, both compounds 6a and 6f with the phenyl carbamate and 4-chlorophenyl carbamate moiety, respectively, were found to exhibit significant activity (T/C > 200%) against murine P388 leukemia in mice, in spite of having IC50 values in the micromolar range. In particular, compound 6f showed the most potent activity with a maximum T/C of 256% at a daily dosage of 4.0 mg/kg for four days. Furthermore, both compounds 6a and 6f were effective against Meth A sarcoma in mice and inhibited 71 and 77% of the tumor growth at 2.0 and 3.0 mg/kg dosages, respectively. In contrast to 6f, compound 6i possessing the 2-nitrophenyl carbamate moiety showed only a slight in vivo activity, while it had about one order of magnitude higher in vitro cytotoxicity than 6f. For the stereochemistry-activity relationships at the C9 position, the (9R*)-isomers of 6c, 6g, and 6j were found to show higher in vitro and in vivo potencies than the corresponding (9S*)-isomers.
一系列从天然动力霉素A简化而来、设计带有各种芳基氨基甲酸酯部分的9-乙酰氧基烯二炔化合物6a - k被合成,并对其DNA切割能力、体外细胞毒性和体内抗肿瘤活性进行了评估。作为关于Rt取代基的构效关系(SAR)研究的结果,分别带有苯基氨基甲酸酯和4-氯苯基氨基甲酸酯部分的化合物6a和6f,尽管其IC50值在微摩尔范围内,但在小鼠体内对鼠P388白血病均表现出显著活性(T/C > 200%)。特别地,化合物6f表现出最强活性,在每日剂量4.0 mg/kg连续给药四天时,最大T/C为256%。此外,化合物6a和6f对小鼠的Meth A肉瘤均有效,在2.0和3.0 mg/kg剂量下分别抑制肿瘤生长71%和77%。与6f相反,带有2-硝基苯基氨基甲酸酯部分的化合物6i在体内仅表现出轻微活性,而其体外细胞毒性比6f高约一个数量级。对于C9位置的立体化学-活性关系,发现6c、6g和6j的(9R*)-异构体在体外和体内的效力均高于相应的(9S*)-异构体。